

1 **Title:** Corowa-kun: Impact of a COVID-19 vaccine information chatbot on vaccine hesitancy, Japan 2021

2
3 **Authors:** Takaaki Kobayashi¹, Yuka Nishina², Hana Tomoi³, Ko Harada⁴, Kyuto Tanaka⁵, Eiyu Matsumoto¹,
4 Kenta Horimukai⁶, Jun Ishihara⁷, Shugo Sasaki⁸, Kanako Inaba⁹, Kyosuke Seguchi¹⁰, Hiromizu Takahashi¹¹,
5 Jorge L. Salinas¹, Yuji Yamada¹²

6
7 **Affiliations:**

8 1: Division of Infectious Disease, Department of Internal Medicine, University of Iowa Hospitals & Clinics, Iowa
9 City, IA, USA

10 2: Department of General Medicine, Juntendo University Faculty of Medicine, Tokyo, Japan

11 3: MSc Public Health (c), Faculty of Public Health and Policy, London School of Hygiene and Tropical Medicine,
12 Keppel Street, London, UK

13 4: Department of General Medicine, Okayama University Graduate School of Medicine, Dentistry and
14 Pharmaceutical Sciences, Okayama, Okayama, Japan

15 5: Division of Pulmonary Medicine, Department of Medicine, Kawasaki Municipal Hospital, Kawasaki,
16 Kanagawa, Japan

17 6: Department of Pediatrics, Jikei University Katsushika Medical Center, Tokyo, Japan

18 7: Department of Bioengineering, Imperial College London, London, United Kingdom

19 8: Department of General Internal Medicine, Saitama Medical University Hospital, Moroyama, Saitama, Japan

20 9: Department of Obstetrics and Gynecology, Kanto Central Hospital, Tokyo, Japan

21 10: Department of Oncology, Kameda Medical Center, Kamogawa, Chiba, Japan

22 11: Department of General Medicine, Juntendo University Faculty of Medicine, Tokyo, Japan

23 12: Brookdale Department of Geriatrics and Palliative Medicine, Icahn School of Medicine at Mount Sinai, New
24 York, New York, USA

25
26 **Corresponding Author:** Takaaki Kobayashi

27 Email: Takaaki-kobayashi@uiowa.edu

28 University of Iowa Hospitals & Clinics; 200 Hawkins Drive, Iowa City, IA

29

30 **A running title (5-6 words):** Chatbot reduced COVID-19 vaccine hesitancy

31 **Abstract word count:** 247

32 **Total word count:** 2619

33 **Number of tables/figures:** 5

34 **Supplemental document/figure:** 3

35 **Number of references:** 37

36 **Key words:** COVID-19, vaccine hesitancy, messenger app, social media, chatbot

37 **Acknowledgement:**

38 We appreciate Shinji Hirooka, Shinsuke Oyama, Hozumi Kaneko, Makiko Sakamoto, Hiroaki Asahara,

39 Ryosuke Kitano for their technical support for Corowa-kun.

40

Abstract

Background: Few studies have assessed how mobile messenger apps affect COVID-19 vaccine hesitancy.

We created a COVID-19 vaccine information chatbot in a popular messenger app in Japan to answer commonly asked questions.

Methods: LINE is the most popular messenger app in Japan. Corowa-kun, a free chatbot, was created in LINE on February 6, 2021. Corowa-kun provides instant, automated answers to frequently asked COVID-19 vaccine questions. In addition, a cross-sectional survey assessing COVID-19 vaccine hesitancy was conducted via Corowa-kun during April 5–12, 2021.

Results: A total of 59,676 persons used Corowa-kun during February–April 2021. Of them, 10,192 users (17%) participated in the survey. Median age was 55 years (range 16–97), and most were female (74%). Intention to receive a COVID-19 vaccine increased from 59% to 80% after using Corowa-kun ($p < 0.01$). Overall, 20% remained hesitant: 16% (1,675) were unsure, and 4% (364) did not intend to be vaccinated. Factors associated with vaccine hesitancy were: age 16 to 34 (odds ratio [OR] = 3.7, 95% confidential interval [CI]: 3.0–4.6, compared to age ≥ 65), female sex (OR = 2.4, CI: 2.1–2.8), and history of a previous vaccine side-effect (OR = 2.5, CI: 2.2–2.9). Being a physician (OR = 0.2, CI: 0.1–0.4) and having received a flu vaccine the prior season (OR = 0.4, CI: 0.3–0.4) were protective.

Conclusions: Corowa-kun reduced vaccine hesitancy by providing COVID-19 vaccine information in a messenger app. Mobile messenger apps could be leveraged to increase COVID-19 vaccine acceptance.

59 **Text**

50 **Background**

51 In 2020, a global coronavirus disease-2019 (COVID-19) pandemic emerged, caused by the SARS-CoV-2
52 virus. [1] According to the World Health Organization, there have been 134 million confirmed cases of COVID-
53 19, including 2.9 million deaths, as of April 8, 2021. [2] Multiple COVID-19 vaccines are highly effective at
54 preventing symptomatic disease. [3] Most developed countries have already vaccinated large proportions of
55 their population. However, many individuals choose not to be vaccinated, often citing safety concerns.
56 Studies in multiple settings have revealed high levels of COVID-19 vaccine hesitancy, ranging from 20–40% of
57 the surveyed populations. [4-8] Vaccine hesitancy differs depending on sociodemographic factors, such as
58 race and educational level, as well as attitudes and beliefs. [9-13] Understanding peoples' concerns about
59 COVID-19 vaccines is necessary to increase vaccine uptake among those who are hesitant.

70
71 Japan has one of the highest vaccine hesitancy rates in the world. According to a previous study, less than
72 30% of people strongly agreed that vaccines were safe, important, or effective. [14] Moreover, Japan has a
73 long history of public concerns about vaccine adverse events. The measles, mumps, and rubella (MMR)
74 vaccine was introduced into the national immunization program in 1989. However, because of reports of
75 aseptic meningitis following the MMR vaccine, the Japanese government withdrew its recommendation for the
76 MMR vaccine in 1993. [15] Human papillomavirus (HPV) vaccination for girls ages 12–16 was first licensed in
77 Japan in October 2009. Acceptance initially reached over 70%, but it fell to less than 1% after extensive media
78 reports of possible adverse events. [16] Ultimately, the Japanese government suspended its recommendation
79 for the vaccine in June 2013. [17]

80
81 Social media are popular in Japan, allowing for circulation of user-generated content and social interaction.
82 Using social media is an integral part of daily life for many people. Leveraging social media platforms to
83 promote vaccines has been investigated. One study revealed that mothers presented with vaccine information
84 on social media during their pregnancy were more likely to vaccinate their infants on time. [18] However, there
85 is a paucity of studies assessing the effect of messenger apps on COVID-19 vaccine acceptance.

36 We created a chatbot in an already existing popular messenger app in Japan to provide people with
37 COVID-19 vaccine information via text messages. We assessed the impact of chatbot text messages on
38 COVID-19 vaccine hesitancy by conducting a cross-sectional survey among chatbot users.

39 40 **Methods**

41 *Corowa-kun: A chatbot with COVID-19 vaccine information in LINE*

42 LINE is a free messenger app available for use in electronic devices, such as smartphones, tablets, and
43 personal computers. LINE users can exchange texts, images, video, and audio. LINE is the most popular
44 messenger app in Japan; about 86 million people in Japan (roughly two-thirds of the population) use this
45 messenger app. [19]

46
47 We created a chatbot in LINE called Corowa-kun's Consultation Room (Corowa-kun) (Figure 1 and
48 supplemental figure 1) to answer COVID-19 vaccine frequently asked questions (FAQs) via text messages.
49 Corowa-kun is free, and anyone using LINE can access it. To create Corowa-kun, we first searched for
50 COVID-19 vaccine FAQs using Japanese government websites and the United States Centers for Disease
51 Control and Prevention website. [20] [21] Fifty questions that we thought were important were selected. We
52 then composed our own corresponding answers to these fifty questions and used them as the initial content for
53 Corowa-kun. Corowa-kun went live in LINE on February 6, 2021. Users have the option to enter free-text
54 questions, and twenty additional FAQs with answers were added based on users' free-text questions entered
55 by April 5, 2021. The public was made aware of Corowa-kun using mass media (e.g. television, radio,
56 newspapers). [22]

57 58 *Corowa-kun users and frequently accessed FAQs*

59 We tracked the total number of users who accessed and used Corowa-kun from February 6 to April 12,
60 2021. We analyzed how frequently each FAQ was accessed from April 5 to 12, 2021. We did not examine
61 frequency of FAQ access before April 5 because new FAQ messages were added prior to then, and the total
62 number of FAQs changed from the initial content in February.

14 *Cross-sectional survey*

15 A cross-sectional survey was conducted using Corowa-kun during April 5–12, 2021. All persons who
16 accessed Corowa-kun by April 12, 2021 were invited within Corowa-kun to participate in the survey. We did
17 not use any incentives, and the survey was completely voluntary. The survey started with three screening
18 questions: (1) “Are you 16 years old or older?”; (2) “Have you received a COVID-19 vaccine?”; and, (3) “Do
19 you agree to participate?”. We included persons ages 16 years old and older who had not received a COVID-
20 19 vaccine. Those who agreed to participate received a link to a Google form. Each LINE account could only
21 answer the survey once.

22
23 The survey was written in Japanese and consisted of 21 questions. To examine attitudes and beliefs
24 regarding COVID-19 vaccines, we included survey items used in similar studies and added our own questions
25 (supplemental document 1). [4] We asked for age, sex, geographic location, educational attainment,
26 employment status, occupation, marriage status, pregnancy status, household members <16 or >64 years old,
27 household size, annual household income, presence of chronic diseases identified as risk factors for severe
28 COVID-19 [21], smoking status, history of influenza vaccine in the previous season, self-rated overall health
29 (scale from 1 to 9 with 9 being best), history of COVID-19, whether they would like to get COVID-19
30 vaccination once available (“I would like to get the vaccine” = Yes, “I am not sure” = Unsure, and “I do not want
31 to get the vaccine” = No). Geographic locations were combined using the following categories: Hokkaido,
32 Tohoku, Kanto (e.g., Tokyo), Chubu, Kansai (e.g., Osaka), Kinki, Chugoku, Shikoku, Kyushu regions, and
33 outside Japan. [23] We asked why they did or did not want to get COVID-19 vaccines using pre-defined
34 answers with a free-text comment (supplemental document 1, respondents could choose multiple answers).
35 Since we aimed to investigate the impact of Corowa-kun on COVID-19 vaccine hesitancy, we also asked
36 whether there was any change in intent to be vaccinated before and after using Corowa-kun.

37 *Statistical analysis*

38
39 Participant characteristics were summarized using frequencies and percentages. For two group
40 comparisons, the Chi-squared test was used for categorical variables and the U-Mann Whitney test was used
41 for continuous variables. For three group comparisons, the Chi-squared test was used for categorical

variables. To identify risk factors for vaccine hesitancy, those responding “No” and “Unsure” were combined (vaccine hesitant) and compared to those responding “Yes”. We fit separate univariate logistic regression models for each exposure, limited to groups with 4 or more persons. We used SAS (version 9, Carey, NC) for statistical analysis. A p-value of 0.05 was considered statistically significant. This study was approved by the institutional review board of Kanto Central Hospital.

Results:

A total of 59,676 persons used Corowa-kun by April 12, 2021. During the cross-sectional survey period (April 5–12, 2021), a total of 14,240 FAQ text messages were used. The most commonly accessed message categories were: “I have (select comorbidity), can I get a COVID-19 vaccine?” (23%); followed by questions on adverse reactions (22%), and how the vaccine works (20%).

Of 59,676 users, 2,472 had the LINE option to block surveys turned on or had inactive account, and 57,235 received the survey invitation. Of those who received it, 10,331 (18.1%) responded to the screening questions. Of those who responded, 139 users were excluded: 26 users were age <16, and 113 users had already received a COVID-19 vaccine. A total of 10,192 (17.1%) were included in the survey analysis. Median age was 55 years (range 16–97), and most were women (74%, table 1). The most common respondent regions were Kansai (42.4%) and Kanto (31.4%, supplemental figure 2). Almost all participants (98%) had a high school diploma or more advanced education. Healthcare workers consisted of 18% of participants: 171 (1.7%) were physicians and 1,723 (16.9%) were healthcare workers other than physicians. Sixty-six participants (0.7%) were pregnant. Participants who lived with someone age ≤ 16 comprised 19.2% of the study population, and those who lived with someone age ≥ 65 were 35.7%. The most common household size was three (25.5%).

Figure 2 displays intent for being vaccinated before and after use of Corowa-kun. Participants who intended to be vaccinated increased after using Corowa-kun ($p < 0.01$). Overall, after use of Corowa-kun, 80.0% of participants intended to be vaccinated (an increase from 59% before use), 16.4% were not sure, and 3.6% did not intend to be vaccinated.

70 Participants who did not intend to be vaccinated or were not sure were combined (vaccine hesitant; n=
71 2,039) and compared to participants who intended to be vaccinated (n=8,153). Table 2 summarizes the
72 factors associated with vaccine hesitancy: Age 16 to 34 (odds ratio [OR] = 3.7, 95% confidential interval [CI]:
73 3.0–4.6, compared to age ≥65), female sex (OR = 2.4, CI: 2.1–2.8), pregnancy (OR = 3.3, CI: 2.0–5.3), and
74 history of vaccine side-effects (OR = 2.5, CI: 2.2–2.9). Being a physician (OR = 0.2, CI: 0.1–0.4, compared to
75 non-healthcare workers) and receiving a flu vaccine in the last influenza season (OR = 0.4, CI: 0.3–0.4) were
76 protective.

77
78 Figure 3 summarizes the reported reasons for vaccine hesitancy or acceptance. The most common
79 reasons for vaccine hesitancy were: “I am worried about vaccine side-effects and/or allergic reactions”
80 (79.7%); followed by, “Many things are not understood about COVID-19 vaccines” (61.8%); and, “I do not think
81 COVID-19 vaccines are safe” (22.2%). The most common reasons for vaccine acceptance were: “I do not
82 want to get infected by COVID-19” (76.0%); followed by, “I do not want to be contagious to others” (74.2%);
83 and, “If I catch COVID-19, I hope that I may only have mild symptoms” (72.5%).

84 **Discussion**

85
86 We created a chatbot to answer COVID-19 vaccine FAQs using the most popular messenger app in Japan.
87 Within two months, nearly 60,000 people accessed Corowa-kun. One-fifth of survey participants were COVID-
88 19 vaccine hesitant. The top risk factors for vaccine hesitancy were younger age, female sex, pregnancy or
89 desire for pregnancy, and previous history of a vaccine side-effect. Protective factors included being a
90 physician and a history of having received a flu vaccine the previous season. COVID-19 vaccine acceptance
91 increased after using Corowa-kun. Corowa-kun, a messenger app chatbot, reached the public with COVID-19
92 vaccine information, helped assess COVID-19 vaccine attitudes, and reassured those with vaccine concerns.

93
94 Besides serving as a socialization platform, social media can help reach those in need of health information.
95 Vaccine content is already widely available across social media platforms. [24] However, there is conflicting
96 data regarding the impact of social media on COVID-19 vaccine hesitancy. Wilson et al. revealed that foreign
97 disinformation campaigns are associated with a drop in mean vaccine coverage over time and an increase in

negative discussions of vaccines. [24] On the other hand, Ahmed et al. found that people who utilize Twitter and Facebook as sources of health information were more likely to be vaccinated. [25] Furthermore, Ortiz et al. revealed that adolescents who fully engaged with social media health platforms improved their health knowledge, and many were likely to have discussions with others about what they learned. [26] We demonstrated that COVID-19 vaccine acceptance increased after using Corowa-kun. Direct communication between healthcare providers and patients is known to reduce vaccine concerns and improve overall uptake. [27] Public trust in doctors and nurses is relatively high in Japan; 26% reported a lot of trust, and 67% reported some trust. [28] Though there was no direct, real-time communication in Corowa-kun, the content was created by ten physicians, and FAQs were added in response to newly-asked questions by users in the free-text section, which might have contributed to the observed positive change. Healthcare providers may need to become more acquainted with social media and utilize these platforms to reduce vaccine hesitancy with more communication between providers and the public. [29]

Our study found relatively higher rates of COVID-19 vaccine acceptance (80%) compared to previously published studies in Japan. Yoda et al. conducted a cross-sectional study in September 2020 and gathered that 66% of participant were willing to be vaccinated against COVID-19 once a vaccine become available. [30] Another survey performed by Machida et al. in January 2021 noted that 62% of respondents were willing to receive a COVID-19 vaccine. [31] Recently, the U.S. CDC reported that the intent to receive a COVID-19 vaccine increased from 39% in September 2020 to 49% in December 2020. [32] Our survey was conducted in the middle of the COVID-19 fourth wave in Japan, and this may have contributed to the increasing trend of vaccine acceptance. A previous study postulated that women may be more hesitant about COVID-19 vaccines. [33] This could be related to the initial absence of vaccine safety and efficacy data for pregnant women. However, a recent U.S. study showed that among persons who received at least one dose of a COVID-19 vaccine, 63% were female. [34] This discrepancy could be because healthcare workers were offered the vaccine first in the United States, and women account for three-fourths of healthcare workers. Newer evidence suggesting that COVID-19 vaccines are safe in pregnancy may help decrease hesitancy. [20]

25 Understanding more about vaccine hesitancy could inform public health efforts. Similar to other studies [4]
26 [32], we found lower vaccine acceptance among younger people, those with lower income and education
27 attainment, active smokers, those with a history of a vaccine side-effect, and those with poor self-reported
28 health. We also found that healthcare workers other than physicians were not as protective as physicians
29 were; healthcare workers other than physicians had similar hesitancy levels as non-healthcare workers.
30 Shekhar et al. revealed that only 8% of healthcare workers did not plan to get a vaccine. [35] However, 80% of
31 their responders were providers (e.g., physicians, nurse practitioners), which might have influenced the high
32 acceptance in their study. Healthcare workers other than physicians may have a greater COVID-19 risk than
33 physicians do: nurses and respiratory therapists often have more direct and prolonged patient contact. Special
34 attention to non-physician healthcare workers may be needed, and efforts to understand and address their
35 concerns are critical. Furthermore, people unemployed due to COVID-19 had low vaccine acceptance.
36 Though not common, 12% of vaccine hesitant respondents mentioned distrust of the government or municipal
37 authorities. Japan has a lower level of public trust in the national government compared to other countries:
38 only 4% reported that they had “a lot” of trust in the government. [28] Because of the known association
39 between low vaccine uptake and government distrust [36], authorities may need to adapt their public health
40 responses and messaging to enhance trustworthiness.

41
42 Our study has limitations. Only users of the most popular social media/messenger app in Japan (“LINE”)
43 could access Corowa-kun. Our results are not representative of those not using this platform or without access
44 to the internet. Approximately three-fourths of participants were women. Only persons with Japanese literacy
45 could answer the survey. Due to the study design—cross-sectional survey—we could not estimate the
46 incidence of vaccine hesitancy. A hypothetical question (“Would you like to receive a COVID-19 vaccine when
47 possible?”) was used because the COVID-19 vaccine was only available for healthcare professionals and for
48 elderly people in a very limited area at the time that the survey was conducted. Finally, the survey answers
49 may not translate into real-world actions by respondents due to other competing priorities and varying
50 epidemiologic and societal conditions at the time a vaccine is available to them. [37] [38]

51 52 **Conclusions**

53 We created Corowa-kun, a free chatbot, to answer COVID-19 vaccine FAQs using the most popular
54 messenger app in Japan. The chatbot was popular, and nearly 10,000 people participated in a cross-sectional
55 survey that helped us identify vaccine hesitancy risk factors. Vaccine hesitancy decreased among Corowa-kun
56 users. Messenger app chatbots may help people obtain appropriate COVID-19 vaccine information in a timely
57 and effective manner.

58
59 **Conflict of Interest:** none

60
61 **Acknowledgement:** We thank Chaorong Wu and Patrick Ten Eyck for useful discussions around study design.
62 (Institute for Clinical and Translational Science, University of Iowa, Iowa City, Iowa, United States)

63
64 **Funding:** none

65
66 **References:**

- 67 1. Zhu N, Zhang D, Wang W, et al. A Novel Coronavirus from Patients with Pneumonia in China, 2019.
68 The New England journal of medicine **2020**; 382(8): 727-33.
- 69 2. World Health Organization. Coronavirus (COVID-19) Dashboard. Available at: <https://covid19.who.int>.
70 Accessed April 10th.
- 71 3. Polack FP, Thomas SJ, Kitchin N, et al. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine.
72 The New England journal of medicine **2020**; 383(27): 2603-15.
- 73 4. Fisher KA, Bloomstone SJ, Walder J, Crawford S, Fouayzi H, Mazor KM. Attitudes Toward a Potential
74 SARS-CoV-2 Vaccine : A Survey of U.S. Adults. Annals of internal medicine **2020**; 173(12): 964-73.
- 75 5. Sherman SM, Smith LE, Sim J, et al. COVID-19 vaccination intention in the UK: results from the
76 COVID-19 vaccination acceptability study (CoVAccS), a nationally representative cross-sectional
77 survey. Hum Vaccin Immunother **2020**: 1-10.
- 78 6. Taylor S, Landry CA, Paluszek MM, Groenewoud R, Rachor GS, Asmundson GJG. A Proactive
79 Approach for Managing COVID-19: The Importance of Understanding the Motivational Roots of
80 Vaccination Hesitancy for SARS-CoV2. Front Psychol **2020**; 11: 575950.

- 31 7. Group C. A future vaccination campaign against COVID-19 at risk of vaccine hesitancy and
32 politicisation. *Lancet Infect Dis* **2020**; 20(7): 769-70.
- 33 8. Lazarus JV, Ratzan SC, Palayew A, et al. A global survey of potential acceptance of a COVID-19
34 vaccine. *Nat Med* **2021**; 27(2): 225-8.
- 35 9. Bell S, Clarke R, Mounier-Jack S, Walker JL, Paterson P. Parents' and guardians' views on the
36 acceptability of a future COVID-19 vaccine: A multi-methods study in England. *Vaccine* **2020**; 38(49):
37 7789-98.
- 38 10. Reiter PL, Pennell ML, Katz ML. Acceptability of a COVID-19 vaccine among adults in the United
39 States: How many people would get vaccinated? *Vaccine* **2020**; 38(42): 6500-7.
- 40 11. Wang J, Jing R, Lai X, et al. Acceptance of COVID-19 Vaccination during the COVID-19 Pandemic in
41 China. *Vaccines (Basel)* **2020**; 8(3).
- 42 12. Leng A, Maitland E, Wang S, Nicholas S, Liu R, Wang J. Individual preferences for COVID-19
43 vaccination in China. *Vaccine* **2021**; 39(2): 247-54.
- 44 13. Szilagyi PG, Thomas K, Shah MD, et al. National Trends in the US Public's Likelihood of Getting a
45 COVID-19 Vaccine-April 1 to December 8, 2020. *JAMA* **2020**.
- 46 14. de Figueiredo A, Simas C, Karafillakis E, Paterson P, Larson HJ. Mapping global trends in vaccine
47 confidence and investigating barriers to vaccine uptake: a large-scale retrospective temporal modelling
48 study. *Lancet* **2020**; 396(10255): 898-908.
- 49 15. Tanaka Y, Ueda Y, Yoshino K, Kimura T. History repeats itself in Japan: Failure to learn from rubella
50 epidemic leads to failure to provide the HPV vaccine. *Hum Vaccin Immunother* **2017**; 13(8): 1859-60.
- 51 16. Hanley SJ, Yoshioka E, Ito Y, Kishi R. HPV vaccination crisis in Japan. *Lancet* **2015**; 385(9987): 2571.
- 52 17. Simms KT, Hanley SJB, Smith MA, Keane A, Canfell K. Impact of HPV vaccine hesitancy on cervical
53 cancer in Japan: a modelling study. *Lancet Public Health* **2020**; 5(4): e223-e34.
- 54 18. Glanz JM, Wagner NM, Narwaney KJ, et al. Web-based Social Media Intervention to Increase Vaccine
55 Acceptance: A Randomized Controlled Trial. *Pediatrics* **2017**; 140(6).
- 56 19. Access and Disparities in Access to Health Care [Internet]. Rockville (MD): Agency for Healthcare
57 Research and Quality. Available at: <http://www.ahrq.gov/research/findings/nhqrdr/nhqdr15/access.html>.
58 Accessed April 24th.


- 19 20. Centers for Disease Control and Prevention. Frequently Asked Questions about COVID-19 Vaccination.
20 Available at: <https://www.cdc.gov/coronavirus/2019-ncov/vaccines/faq.html>. Accessed April 30.
- 21 21. Ministry of Health, Labour and Welfare. Novel Coronavirus (COVID-19). Available at:
22 https://www.mhlw.go.jp/stf/seisakunitsuite/bunya/0000164708_00079.html. Accessed April 30th.
- 23 22. Cartoon dog pitches COVID vaccines to sceptical Japanese public. Reuters. Available at:
24 [https://www.reuters.com/artcile/article/us-health-coronavirus-japan-vaccine/cartoon-dog-pitches-covid-](https://www.reuters.com/artcile/article/us-health-coronavirus-japan-vaccine/cartoon-dog-pitches-covid-vaccines-to-sceptical-japanese-public-idUSKBN2AC0BB)
25 [vaccines-to-sceptical-japanese-public-idUSKBN2AC0BB](https://www.reuters.com/artcile/article/us-health-coronavirus-japan-vaccine/cartoon-dog-pitches-covid-vaccines-to-sceptical-japanese-public-idUSKBN2AC0BB). Accessed May 13.
- 26 23. Japan's Diverse Regions. JAPANGOV. THE GOVERNMENT OF JAPAN. Available at:
27 <https://www.japan.go.jp/regions/index.html>.
- 28 24. Wilson SL, Wiysonge C. Social media and vaccine hesitancy. *BMJ Glob Health* **2020**; 5(10).
- 29 25. Ahmed N, Quinn SC, Hancock GR, Freimuth VS, Jamison A. Social media use and influenza vaccine
30 uptake among White and African American adults. *Vaccine* **2018**; 36(49): 7556-61.
- 31 26. Ortiz RR, Shafer A, Cates J, Coyne-Beasley T. Development and Evaluation of a Social Media Health
32 Intervention to Improve Adolescents' Knowledge About and Vaccination Against the Human
33 Papillomavirus. *Glob Pediatr Health* **2018**; 5: 2333794X18777918.
- 34 27. N.L. Oh, C.B. Biddell, B.E. Rhodes, et al., Provider communication and HPV vaccine uptake: A meta-
analysis and systematic review, *Preventive Medicine* (2021), <https://doi.org/10.1016/j.ypmed.2021.106554>.
- 28 28. GALLUP. Wellcome Global Monitor. How dose the world feel about science and health? Country data
29 2018. Available at: <https://wellcome.org/sites/default/files/wgm2018-country-data-all.pdf>. Accessed May
30 22.
- 31 29. Marcelin JR, Cortes-Penfield N, Del Rio C, et al. How the Field of Infectious Diseases Can Leverage
32 Digital Strategy and Social Media Use During a Pandemic. *Open Forum Infect Dis* **2021**; 8(2): ofab027.
- 33 30. Yoda T, Katsuyama H. Willingness to Receive COVID-19 Vaccination in Japan. *Vaccines (Basel)* **2021**;
34 9(1).
- 35 31. Machida M, Nakamura I, Kojima T, et al. Acceptance of a COVID-19 Vaccine in Japan during the
36 COVID-19 Pandemic. *Vaccines (Basel)* **2021**; 9(3).

- 35 32. Nguyen KH, Srivastav A, Razzaghi H, et al. COVID-19 Vaccination Intent, Perceptions, and Reasons
36 for Not Vaccinating Among Groups Prioritized for Early Vaccination - United States, September and
37 December 2020. *MMWR Morbidity and mortality weekly report* **2021**; 70(6): 217-22.
- 38 33. Robertson E, Reeve KS, Niedzwiedz CL, et al. Predictors of COVID-19 vaccine hesitancy in the UK
39 household longitudinal study. *Brain Behav Immun* **2021**; 94: 41-50.
- 40 34. Painter EM, Ussery EN, Patel A, et al. Demographic Characteristics of Persons Vaccinated During the
41 First Month of the COVID-19 Vaccination Program - United States, December 14, 2020-January 14,
42 2021. *MMWR Morbidity and mortality weekly report* **2021**; 70(5): 174-7.
- 43 35. Shekhar R, Sheikh AB, Upadhyay S, et al. COVID-19 Vaccine Acceptance among Health Care
44 Workers in the United States. *Vaccines (Basel)* **2021**; 9(2).
- 45 36. Miyachi T, Takita M, Senoo Y, Yamamoto K. Lower trust in national government links to no history of
46 vaccination. *Lancet* **2020**; 395(10217): 31-2.
- 47 37. Stern MF, Piasecki AM, Strick LB, et al. Willingness to Receive a COVID-19 Vaccination Among
48 Incarcerated or Detained Persons in Correctional and Detention Facilities - Four States, September-
49 December 2020. *MMWR Morbidity and mortality weekly report* **2021**; 70(13): 473-7.
- 50 38. Ajzen I, Brown TC, Carvajal F. Explaining the discrepancy between intentions and actions: the case of
51 hypothetical bias in contingent valuation. *Pers Soc Psychol Bull* **2004**; 30(9): 1108-21.
- 52

53

54 **Figure 1: Corowa-kun's Consultation Room: a free messenger app chatbot, Japan 2021**

How does Corowa-kun work?




55

56 Corowa-kun is the mascot of an online chatbot. This chatbot in LINE is used to answer COVID-19 vaccine

57 frequently asked questions (FAQs) via text messages. As of May 10th, 70 FAQs are available.

58

59 **Figure 2: COVID-19 vaccine acceptance increased and hesitancy decreased after using Corowa-kun,**
50 **Japan, 2021 (n=10,192)**



51

52 *There was a statistically significant difference in responses between before and after using Corowa-kun ($p < 0.01$, Chi-square
53 test)

54

55

Table 1: Characteristics of the COVID-19 vaccine survey participants, Japan, 2021 (n=10,192)

	Total	Intend to get vaccinated	Do not intend to get vaccinated	Unsure
Characteristics	N=10,192	N= 8,153	N= 364	N= 1,675
Sociodemographic				
Age				
Mean (SD)	54 (12)	54.6 (12.4)	48.6 (12.8)	50.6 (11.4)
Age category				
16-34	798 (7.8%)	569 (7.0%)	61 (16.8%)	168 (10.0%)
35-49	2694 (26.4%)	2046 (25.1%)	122 (33.5%)	526 (31.4%)
50-64	4562 (44.8%)	3609 (44.3%)	143 (39.3%)	810 (48.4%)
≥65	2138 (21.0%)	1929 (23.7%)	38 (10.4%)	171 (10.2%)
Sex				
Male	2556 (25.1%)	2778 (27.9%)	62 (17.0%)	216 (12.9%)
Female	7543 (74.0%)	5816 (71.3%)	292 (80.2%)	1435 (85.7%)
Other	17 (0.2%)	14 (0.2%)	1 (0.3%)	2 (0.1%)
No answer	76 (0.8%)	45 (0.6%)	9 (2.5%)	22 (1.3%)
Region				
Hokkaido	270 (2.7%)	198 (2.4%)	15 (4.1%)	57 (3.4%)
Tohoku	315 (3.1%)	236 (2.9%)	11 (3.0%)	68 (4.1%)
Kanto	3203 (31.4%)	2606 (32.0%)	118 (32.4%)	479 (28.6%)
Chubu	1091 (10.7%)	868 (10.7%)	38 (10.4%)	185 (11.0%)
Kansai	4325 (42.4%)	3497 (42.9%)	125 (34.3%)	703 (42.0%)
Chugoku	271 (2.7%)	214 (2.6%)	14 (3.9%)	43 (2.6%)
Shikoku	156 (1.5%)	109 (1.3%)	9 (2.5%)	38 (2.3%)
Kyusyu	527 (5.2%)	399 (4.9%)	31 (8.5%)	97 (5.8%)
Abroad	34 (0.3%)	26 (0.3%)	3 (0.8%)	5 (0.3%)
Educational attainment				
Elementary or junior high school	208 (2.0%)	151 (1.9%)	10 (2.8%)	47 (2.8%)
High school	2688 (26.2%)	2008 (24.6%)	119 (32.7%)	541 (32.3%)
College or professional school	3365 (33.0%)	2635 (32.3%)	121 (33.2%)	609 (36.4%)
Undergraduate school	3502 (34.4%)	2966 (36.4%)	100 (27.5%)	436 (26.0%)
Postgraduate school	449 (4.4%)	393 (4.8%)	14 (3.9%)	42 (2.5%)
Employment status				
Full-time	3866 (37.9%)	3142 (38.5%)	142 (39.0%)	582 (34.8%)
Part-time	2728 (26.8%)	2097 (25.7%)	114 (31.3%)	517 (30.9%)
Student	100 (1.0%)	73 (0.9%)	3 (0.8%)	24 (1.4%)
Retired	740 (7.3%)	681 (8.4%)	9 (2.5%)	50 (3.0%)
Homemaker	1992 (19.5%)	1555 (19.1%)	69 (19.0%)	368 (22.0%)
Unemployed due to COVID-19	128 (1.3%)	91 (1.1%)	6 (1.7%)	31 (1.9%)
Unemployed irrelevant to COVID-19	638 (6.3%)	514 (6.3%)	21 (5.8%)	103 (6.2%)
Healthcare worker				
Physician	171 (1.7%)	164 (2.0%)	3 (0.8%)	4 (0.2%)
Yes, other than physician	1723 (16.9%)	1400 (17.2%)	75 (20.6%)	248 (14.8%)
No	8298 (81.4%)	6589 (80.8%)	286 (78.6%)	1423 (85.0%)
Marriage status				
Married	7412 (72.7%)	6038 (74.1%)	218 (59.9%)	1156 (69.0%)
Never married	1841 (18.1%)	1409 (17.3%)	94 (25.8%)	338 (20.2%)
Divorced	939 (9.2%)	706 (8.7%)	52 (14.3%)	181 (10.8%)
Living with persons at age<16				
	1958 (19.2%)	1506 (18.5%)	81 (22.3%)	371 (22.2%)
Living with persons at age≥65				
	3641 (35.7%)	2994 (36.7%)	112 (30.8%)	535 (31.9%)
Household size				
1	1499 (14.8%)	1199 (14.8%)	65 (18.2%)	235 (14.2%)
2	3685 (36.5%)	3025 (37.4%)	119 (33.3%)	541 (32.6%)
3	2577 (25.5%)	2009 (24.8%)	88 (24.7%)	480 (29.0%)
4	1576 (15.6%)	1266 (15.7%)	52 (14.6%)	258 (15.6%)
5	500 (5.0%)	383 (4.7%)	21 (5.9%)	96 (5.8%)
≥6	265 (2.6%)	205 (2.5%)	12 (3.4%)	48 (2.9%)
Annual household income				
Less than JPY 2 million	4592 (45.1%)	3503 (43.0%)	160 (44.0%)	929 (55.5%)
JPY 200 million < JPY 400 million	2823 (27.7%)	2286 (28.0%)	110 (30.2%)	427 (25.5%)
JPY 400 million < JPY 600 million	1449 (14.2%)	1214 (14.9%)	56 (15.4%)	179 (10.7%)

JPY 600 million < JPY 800 million	664 (6.5%)	560 (6.9%)	21 (5.8%)	83 (5.0%)
JPY 800 million or higher	664 (6.5%)	590 (7.2%)	17 (4.7%)	57 (3.4%)
Health status				
Chronic respiratory disease	795 (7.8%)	588 (7.2%)	41 (11.3%)	166 (9.9%)
Chronic heart disease	1419 (13.9%)	1190 (14.6%)	31 (8.5%)	198 (11.8%)
Chronic kidney disease	152 (1.5%)	130 (1.6%)	6 (1.7%)	16 (1.0%)
Chronic liver disease	84 (0.8%)	70 (0.9%)	2 (0.6%)	12 (0.7%)
Diabetes mellitus	529 (5.2%)	439 (5.4%)	15 (4.1%)	75 (4.5%)
Blood disease except for anaemia	154 (1.5%)	119 (1.5%)	9 (2.5%)	26 (1.6%)
Malignancy	216 (2.1%)	149 (1.8%)	17 (4.7%)	50 (3.0%)
Receiving immunosuppressant	309 (3.0%)	224 (2.8%)	14 (3.9%)	71 (4.2%)
Neurological or neuromuscular disease due to immune deficiency	60 (0.6%)	36 (0.4%)	5 (1.4%)	19 (1.1%)
Physical decline associated with a neurological disease or a neuromuscular disease	34 (0.3%)	23 (0.3%)	1 (0.3%)	10 (0.6%)
Chromosomal abnormality	14 (0.1%)	11 (0.1%)	1 (0.3%)	2 (0.1%)
Severe psychosomatic disorder	7 (0.07%)	3 (0.04%)	2 (0.6%)	2 (0.1%)
Sleep apnoea	271 (2.7%)	224 (2.8%)	11 (3.0%)	36 (2.2%)
Obesity	936 (9.2%)	704 (8.6%)	24 (6.6%)	208 (12.4%)
No underlying health condition	5862 (57.5%)	4767 (58.5%)	219 (60.2%)	876 (52.3%)
Smoking status				
Active smoker	922 (9.1%)	690 (8.5%)	47 (12.9%)	185 (11.0%)
Former smoker	2435 (23.9%)	1987 (24.4%)	83 (22.8%)	365 (21.8%)
Only electronic cigarettes	278 (2.7%)	237 (2.9%)	8 (2.2%)	33 (2.0%)
Never smoker	6557 (64.3%)	5239 (64.3%)	226 (62.1%)	1092 (65.2%)
Have you had a flu shot within the past year?	7037 (69.0%)	5998 (73.6%)	131 (36.0%)	908 (54.2%)
Self-reported history of COVID-19				
Yes (I tested positive)	58 (0.6%)	48 (0.6%)	3 (0.8%)	7 (0.4%)
Yes (I had the symptoms but did not receive a positive test)	83 (0.8%)	60 (0.7%)	5 (1.4%)	18 (1.1%)
No	10051 (98.6%)	8045 (98.7%)	356 (97.8%)	1650 (98.5%)
Have you had any vaccine side-effects?				
Yes	975 (9.6%)	644 (7.9%)	85 (23.4%)	246 (14.7%)
No	8475 (83.2%)	7051 (86.5%)	238 (65.4%)	1186 (70.8%)
Unsure	742 (7.3%)	458 (5.6%)	41 (11.3%)	243 (14.5%)
Self-reported overall health				
1-3	116 (1.1%)	76 (0.9%)	11 (3.0%)	29 (1.7%)
4-6	5430 (53.3%)	4144 (50.8%)	222 (61.0%)	1064 (63.5%)
7-9	4646 (45.6%)	3933 (48.2%)	131 (36.0%)	582 (34.8%)
Pregnancy status				
Pregnant	67 (0.7%)	36 (0.4%)	5 (1.4%)	26 (1.6%)
Not pregnant	5159 (50.6%)	4087 (50.1%)	176 (48.4%)	896 (53.5%)
Desire to be pregnant	228 (2.2%)	144 (1.8%)	26 (7.1%)	58 (3.5%)
Not applicable	4738 (46.5%)	3886 (47.7%)	157 (43.1%)	695 (41.5%)

56 **Table 2: Univariable logistic regression models of factors associated with COVID-19 vaccine hesitancy,**
 57 **Japan, 2021 (n=10,192)**

	Vaccine hesitancy N=2,039		Vaccine acceptance N=8,153		Odds ratio
Age					
16-34	229	11.2%	569	7.0%	3.7 (3.0-4.6)
35-49	648	31.8%	2046	25.1%	2.9 (2.5-3.5)
50-64	953	46.7%	3609	44.3%	2.4 (2.1-2.9)
≥65	209	10.3%	1929	23.7%	Ref
Sex					
Male	278	13.63%	2278	27.9%	Ref
Female	1727	84.7%	5816	71.3%	2.4 (2.1-2.8)
Other	3	0.2%	14	0.2%	NA
No answer	31	1.5%	45	0.6%	5.6 (3.5-9.1)
Region					
Hokkaido	72	3.5%	198	2.4%	1.6 (1.2-2.1)
Tohoku	79	3.9%	236	2.9%	1.5 (1.1-1.9)
Kanto	597	29.3%	2606	32.0%	Ref
Chubu	223	10.9%	868	10.7%	1.1 (0.9-1.3)
Kansai	828	40.6%	3497	42.9%	1.0 (0.9-1.2)
Chugoku	57	2.8%	214	2.6%	1.2 (0.9-1.6)
Shikoku	47	2.3%	109	1.3%	1.8 (1.3-2.6)
Kyusyu	128	6.3%	399	1.9%	1.4 (1.1-1.7)
Abroad	8	0.4%	26	0.3%	1.3 (0.6-3.0)
Educational attainment					
Elementary or junior high school	57	2.8%	151	1.9%	1.4 (1.0-1.9)
High school	660	32.4%	2008	24.6%	1.2 (1.1-1.3)
College or professional school	730	35.8%	2635	32.3%	Ref
Undergraduate school	536	26.3%	2966	36.4%	0.7 (0.6-0.7)
Postgraduate school	56	2.8%	393	4.8%	0.5 (0.4-0.7)
Employment status					
Full-time	724	35.5%	3142	38.5%	Ref
Part-time	631	31.0%	2097	25.7%	1.3 (1.2-1.5)
Student	27	1.3%	73	0.9%	1.6 (1.0-2.5)
Retired	59	2.9%	681	8.4%	0.4 (0.3-0.5)
Homemaker	437	21.4%	1555	19.1%	1.2 (1.1-1.4)
Unemployed due to COVID-19	37	1.8%	91	1.1%	1.8 (1.2-2.6)
Unemployed irrelevant to COVID-19	124	6.1%	514	6.3%	1.0 (0.8-1.3)
Healthcare worker					
Physician	7	0.3%	164	2.0%	0.2 (0.1-0.4)
Yes, but not physician	323	15.8%	1400	17.2%	0.9 (0.8-1.01)
No	1709	83.8%	6589	80.8%	Ref
Marriage status					
Married	1374	67.4%	6038	47.1%	Ref
Never married	432	21.2%	1409	17.3%	1.3 (1.2-1.5)
Divorced	233	11.4%	706	8.7%	1.5 (1.2-1.7)
Living with persons at age<16					
	452	22.2%	1506	18.5%	1.3 (1.1-1.4)
Living with persons at age≥65					
	647	31.8%	2994	36.7%	0.8 (0.7-0.9)
Household size					
1	300	14.9%	1199	14.8%	Ref
2	660	32.8%	3025	37.4%	0.9 (0.7-1.0)
3	568	28.2%	2009	24.8%	1.1 (1.0-1.3)
4	310	15.4%	1266	15.7%	1.0 (0.8-1.2)
5	117	5.8%	383	4.8%	1.2 (1.0-1.6)
≥6	60	3.0%	205	2.5%	1.2 (0.9-1.6)
Annual household income					
Less than JPY 2 million	1089	53.4%	3503	43.0%	1.6 (1.4-1.9)
JPY 200 million < JPY 400 million	537	26.3%	2286	28.0%	1.2 (1.0-1.4)
JPY 400 million < JPY 600 million	235	11.5%	1214	14.9%	Ref
JPY 600 million < JPY 800 million	104	5.1%	560	6.9%	1.0 (0.7-1.2)
JPY 800 million or higher	74	3.6%	590	7.2%	0.7 (0.5-0.9)
Chronic respiratory disease					
	207	10.2%	588	7.2%	1.5 (1.2-1.7)
Chronic heart disease					
	229	11.2%	1190	14.6%	0.7 (0.6-0.9)
Chronic kidney disease					
	22	1.1%	130	1.6%	0.7 (0.4-1.1)

Chronic liver disease	14	0.7%	70	0.9%	0.8 (0.4-1.4)
Diabetes mellitus	90	4.4%	439	5.4%	0.8 (0.6-1.0)
Blood disease except for anaemia	35	1.7%	119	1.5%	1.2 (0.8-1.7)
Malignancy	67	3.3%	149	1.8%	1.8 (1.4-2.4)
Receiving immunosuppressant	85	4.2%	224	2.3%	1.5 (1.2-2.0)
Neurological or neuromuscular disease due to immune deficiency	24	1.2%	36	0.4%	2.7 (1.6-4.5)
Physical decline associated with a neurological disease or a neuromuscular disease	11	0.5%	23	0.3%	1.9 (0.9-3.9)
Chromosomal abnormality	3	0.2%	11	0.1%	NA
Severe psychosomatic disorder	4	0.2%	3	0.04%	NA
Sleep apnoea	47	2.3%	224	2.8%	0.8 (0.6-1.1)
Obesity	232	11.4%	704	8.6%	1.4 (1.2-1.6)
No underlying health condition	1095	53.7%	4767	58.5%	0.8 (0.7-0.9)
Smoking status					
Active smoker	232	11.4%	690	8.5%	1.3 (1.1-1.6)
Former smoker	448	22.0%	1987	24.4%	0.9 (0.8-1.0)
Only electronic cigarettes	41	2.0%	237	2.9%	0.7 (0.5-1.0)
Never smoker	1318	64.6%	5239	64.3%	
Have you had a flu shot within the past year?	1039	51%	5998	73.6%	0.4 (0.3-0.4)
Self-reported history of COVID-19					
Yes (I tested positive)	48	0.6%	10	0.5%	0.8 (0.4-1.7)
Yes (I had the symptoms but did not receive a positive test)	60	0.7%	23	1.1%	1.5 (0.9-2.5)
No	8045	80%	2006	98.4%	Ref
Have you had any vaccine side-effects?					
Yes	331	16.2%	644	7.9%	2.5 (2.2-2.9)
No	1424	69.8%	7051	86.5%	Ref
Unsure	284	13.9%	458	5.6%	3.1 (2.6-3.6)
Self-reported overall health					
1-3	40	2.0%	76	0.9%	1.7 (1.2-2.5)
4-6	1286	63.1%	4144	50.8%	Ref
7-9	713	35.0%	3933	48.2%	0.6 (0.5-0.6)
Pregnancy status					
Pregnant	31	1.5%	36	0.4%	3.3 (2.0-5.3)
Not pregnant	1072	52.57 %	4087	50.1%	Ref
Desire to be pregnant	84	4.1%	144	1.8%	2.2 (1.7-2.9)
Not applicable	852	41.8%	3886	47.7%	0.8 (0.8-0.9)

58

59 Ref: reference

70 NA: Logistic regression was not performed due to too small number (n≤3).

71

72 **Figure 3: Reasons provided for COVID-19 hesitancy (A) and acceptance (B), COVID-19 vaccine survey,**

73 **Japan, 2021**



74

75

76